Talk:Julphar

Semi-protected edit request on 10 October 2018

Please change the following from the original article:

"Julphar (Gulf Pharmaceutical Industries) is a public shareholding pharmaceutical company based in Diqdaqah, Ras Al Khaimah, United Arab Emirates. It was established in 1980 under Sheikh Saqr bin Mohammad al-Qassimi, the late ruler of Ras Al Khaimah and currently produces and distributes pharmaceutical products across five continents.

Julphar produces therapeutic products which target a large range of pharmaceutical segments including consumer, endocrinology, antibiotics, cardiovascular, women's health, dermatology and gastroenterology."

To the following:

"Julphar (Gulf Pharmaceutical Industries) is a public shareholding pharmaceutical company headquartered in Ras Al Khaimah, United Arab Emirates. The multinational company is organized into three globally operating business units – Julphar General Medicines, Julphar Diabetes Solutions and Julphar Life.

Julphar employs more than 5,000 people and distributes pharmaceutical products to more than 50 countries on five continents. . The company manufactures a wide range of products that target major therapeutic segments including Gastrointestinal Tract, Respiratory, Pain Management, Wounds and Scars, Anti-infectives, Anemia, Gynecology, Dermatology, Erectile Dysfunction and Cardiology.

Julphar has 16 internationally accredited facilities in Africa, the Middle East and Asia that produce more than a million boxes of medicine a day including tablets, syrups, suspensions, creams and injectables. . In 2012, the company became one of the world’s largest producers of insulin with its state-of-the-art UAE-based biotechnology facility.

In the fiscal year 2017, Julphar reported sales of AED 1.273 billion and a net profit of AED 90.3 million. . The company reported sales of AED 558 million and a net profit of AED 48 million for the first half of 2018.

In February 2018, it was announced that Julphar had been ranked as the number one pharmaceutical company in the UAE in terms of market share.

AND

Please change the side bar items from:

"Type: Public shareholding Company Industry: Pharmaceutical, biotechnology Founded: March 30, 1980 Headquarters: RAK, UAE Key people: Sheikh Faisal bin Saqr Al Qasimi Chairman of the Board Dr. Ayman Ahmed Sahli CEO Products: Julphar manufacture and sell more than 213 products Revenue: AED 1.43 billion (2014) Operating income: AED 238.5 million (2014) Net income: AED 234.7 million (2014) Number of employees: 2900 Website: www.julphar.net"

to

"Type: Public Shareholding Company Traded as: ADX: Julphar Industry: Pharmaceutical, biotechnology Founded: 1980 Headquarters: Ras Al Khaimah, UAE Area served: Worldwide Key people: Sheikh Faisal Bin Saqr Al Qasimi (Chairman of the Board) Jerome Carle (General Manager) Products: Pharmaceuticals, vaccines, over-the-counter medicines Revenue: AED 1.273 billion (2017) Operating profit: AED 111 million (2017) Net profit: AED 90 million (2017) Number of employees: 5000 Subsidiaries: Planet Pharmacies, Gulf Inject, MenaCool Website: www.julphar.net"

Please change the following:

"One of Julphar’s strategic products include Moist Exposure Burn Ointment (MEBO), a common product used for burns. The success of MEBO led to the creation of MEBO Scar, an ointment which was developed specifically by Julphar for the treatment of scars both old and new, and is used to restore the health of traumatized skin. MEBO Scar assists patients with both functional and cosmetic problems caused by scarring.

In 2012, Julphar will become the only company in the Middle East and North Africa Region to locally produce Recombinant DNA(r-DNA), the raw material used to make insulin.[citation needed] Julphar Diabetes—a division of Julphar that will manage the manufacturing and commercialization the company’s diabetes products—has the facility to produce approximately 40 million vials of insulin per year. In 2011, Julphar signed a partnership with International Diabetes Federation (IDF). Diabetes rates in the MENA are amongst the highest in the world. IDF estimates that in 2011, 32.6 million people are living with diabetes in the region, and this is expected to increase by over 80% by 2030.

Julphar maintains a network of eleven manufacturing plants based in the UAE, with plans to open additional facilities in strategic countries such as Kingdom of Saudi Arabia, Ethiopia and Algeria. In 2011, Julphar signed an agreement with Saudi-based Cigalah Group, to build an independent manufacturing facility in the western region of KSA, in a project worth US$40 million.

In 2011, Julphar crossed AED 1billion in sales, an 11.3% growth from 2010.[12] In January 2013, Julphar launched its first international facility in Addis Ababa Ethiopia. This facility has the capacity to produce 25 million bottles, 50 million tablets and 170 million capsules per year.[13]"

To:

"Julphar is organized into three globally operating business units – Julphar General Medicines, Julphar Diabetes Solutions and Julphar Life. The company’s wide range of products target major therapeutic segments including Gastrointestinal Tract, Respiratory, Pain Management, Wounds and Scars, Anti-infectives, Anemia, Gynecology, Dermatology, Erectile Dysfunction and Cardiology."

PLEASE CREATE A NEW SECTION CALLED "HISTORY" AND ADD THE BELOW TO IT

Julphar was established and registered as public shareholding company, Gulf Pharmaceutical Industries, in 1980 under the guidance of His Highness Sheikh Saqr Bin Mohammad Al Qassimi, the late ruler of Ras Al Khaimah. In 1984, the company started producing non-sterile solid dosage medicines and later that year, obtained approval for 30 products from the Ministry of Health and Prevention.

By 1990, Julphar had established distribution agents in the United States, Germany, Ecuador, Saudi Arabia, Oman, Qatar, Jordan, Yemen, Sudan and Pakistan. In 2003, the company launched its biotechnology facility, Julphar VII, which began producing erythropoietin, interferon, Granulocyte-colony stimulating factor (GCSF) and interleukin. Julphar’s transportation division MenaCool was launched in 2008, which today comprises a fleet of 40 temperature and humidity controlled vehicles that is supported by air, sea and freight.

The company signed an agreement with Saudi Arabia-based company Cigalah Group in 2011 to build an independent manufacturing facility in the western region of the Kingdom – a project worth SAR 300 million. In 2012, Julphar started producing biosimilars and in the same year launched Julphar Diabetes Solutions.

In conjunction with its local Ethiopian partner Medtech, Julphar officially inaugurated its first manufacturing facility outside of the UAE in 2013. Based in the Ethiopian capital, Addis Ababa, Julphar Ethiopia today produces 500 million tablets, 100 million capsules, 15 million bottles of syrups and suspensions, and 2 million tubes of ointments a year.

Two years later in 2015, the company acquired a majority stake in Bangladesh-based RAK Pharmaceuticals (now Julphar Bangladesh) for USD9.5 million marking its entry into the Bangladeshi market. Julphar Bangladesh today produces 300 million tablets, 150 million capsules, 2 million bottles of dry powder and 2 million tubes of ointments a year.

In 2017, Julphar took its overseas production bases to three with the official opening of its manufacturing facility in King Abdullah Economic City (KAEC), Saudi Arabia. The state-of-the-art plant has the capacity to produce 1 billion tablets, 300 million capsules and 30 million bottles of syrups and suspensions a year.

The following year, in 2018, Julphar Saudi Arabia was granted Current Good Manufacturing Practice (cGMP) approval by the Saudi Food and Drug Authority (SFDA) becoming the first pharmaceutical company in KAEC to earn full cGMP certification on its first inspection.

PLEASE ADD A SECTION CALLED PRODUCTS AND ADD THE BELOW TO IT

MEBO One of Julphar’s strategic products is Moist Exposure Burn Ointment (MEBO), a product used for burns. The success of MEBO led to the creation of MEBO Scar, an ointment which was developed specifically by Julphar for the treatment of scars both old and new, and is used to restore the health of traumatized skin. MEBO Scar assists patients with both functional and cosmetic problems caused by scarring.

PLEASE ADD A SECTION CALLED BIOTECHNOLOGY AND ADD THE BELOW TO IT

Julphar Diabetes Solutions was established in 2012 and coincided with the launch of a $150m biopharmaceutical facility, which has the capacity to produce 1,500kg of recombinant human insulin and insulin analogues crystals (rDNA), equivalent to a combination of 30 million vials & 25 million cartridges and pens of insulin per year. Julphar Diabetes Solutions produces insulin, DPP4 Inhibitors, medical devices, active ingredients and oral anti-diabetics and is now one of the largest producers of insulin in the world.

In August 2018, Julphar signed an agreement with global medical technology company, BD (Becton, Dickinson and Company), to supply disposable insulin pens in the United Arab Emirates (UAE). Through this agreement, Julphar’s human insulin formulations including Jusline R, Jusline N and Jusline 30/70 will be available for administration through BD’s portfolio of BD Vystra™ disposable pens. In addition, the same device will be used for insulin analogues (insulin glargine and insulin lispro), which are still under development.

PLEASE CREATE A NEW SECTION CALLED PARTNERSHIPS AND ADD THE BELOW TO IT:

In 2014, Julphar signed a five-year licensing deal with global healthcare leader MSD. The deal gives Julphar exclusive rights to produce, market, distribute and sell MSD medicines in the UAE, Kuwait, Bahrain, Oman and Iraq. In 2018, the alliance won the ASAP award - the first time for a pharmaceutical company from region.

PLEASE REMOVE: ‘Board of Directors’ section ‘Gallery’ section Anthonypermal (talk) 10:31, 10 October 2018 (UTC) Anthonypermal (talk) 10:31, 10 October 2018 (UTC)

References

 Partly done: @Anthonypermal: I removed the last three sections, but the rest of what you have listed amounts to a complete and pretty significant rewrite of the article. This is more than what is intended with an edit request. I believe consensus is needed for these changes before they are implemented. Dolotta (talk) 21:42, 12 October 2018 (UTC)

@Dolotta: Thank you. Based on the information provided - with citations - can at least the CEO details be updated? Ayman hasn't been CEO for a while now. Second, what is needed for consensus to be arrived at? Thanks again. Anthonypermal (talk) 04:33, 14 October 2018 (UTC)

@Dolotta: Please change the CEO's name. He hasn't been CEO for more than 2 years. Please amend with the current CEO's name as cited in the amendments requested above earlier. I'm not sure why that is not changed yet despite it being a confirmed fact. Anthonypermal (talk) 07:33, 28 October 2018 (UTC)

@Anthonypermal: There doesn't appear to be a direct reference for the CEO change, although there are references for other portions of the proposed changes to the info box. Would you be able to spell it out? When you respond, feel free to reset the ans= option in the edit request as well. My Wikipedia time may be limited by my life in the real world this week. Thanks! -- Dolotta (talk) 22:17, 28 October 2018 (UTC)

@Dolotta: Hey Dolotta, here's the reference to the change of CEO of the company. The CEO left and now the company has a General Manager instead. Here's the reference, it's from an independent news article and interview. After that reference I've also added a reference of the corporate website of the company as well that shows his role as General Manager. and Please can you change this? Anthonypermal (talk) 05:09, 17 December 2018 (UTC)

 Not done: please submit a new edit request omitting the parts which have been implemented. SITH (talk) 17:21, 11 January 2019 (UTC)

Semi-protected edit request on 27 March 2019

Please remove Ayman Sahli as the CEO. The GM, Jerome Carle, was appointed two years ago. See link for reference: http://www.julphar.net/en/about-us/executive-team CocaJola123 (talk) 08:46, 27 March 2019 (UTC)

 Done NiciVampireHeart 22:19, 27 March 2019 (UTC)

Semi-protected edit request on 28 March 2019

Please change net sales from AED 1.43 billion (2014) to AED 863 million (2018). Link for reference: https://www.zawya.com/uae/en/companies/story/Julphar_announces_2018_preliminary_results-ZAWYA20190214112144/

CocaJola123 (talk) 04:30, 28 March 2019 (UTC) CocaJola123 (talk) 04:30, 28 March 2019 (UTC)

Not done: You should be able to edit the page now that you are autoconfirmed. --DannyS712 (talk) 03:00, 8 April 2019 (UTC)

Semi-protected edit request on 28 March 2019

Please add the following sentence to the end of the first para: "In February 2018, it was announced that Julphar had been ranked as the number one pharmaceutical company in the UAE in terms of market share". Link for reference: http://tradearabia.com/news/IND_338601.html

CocaJola123 (talk) 04:35, 28 March 2019 (UTC) CocaJola123 (talk) 04:35, 28 March 2019 (UTC)

Not done: You should be able to edit the page now that you are autoconfirmed. --DannyS712 (talk) 03:02, 8 April 2019 (UTC)

Semi-protected edit request on 28 March 2019

Please change in the info in the right hand box for number of employees from 2900 to 5000. Link for reference: http://www.julphar.net/en/about-us/julphar-glance

CocaJola123 (talk) 04:39, 28 March 2019 (UTC) CocaJola123 (talk) 04:39, 28 March 2019 (UTC)

Not done: You should be able to edit the page now that you are autoconfirmed. --DannyS712 (talk) 03:02, 8 April 2019 (UTC)

Semi-protected edit request on 28 March 2019

Please chance the opening sentence

from: Julphar (Gulf Pharmaceutical Industries) is a public shareholding pharmaceutical company based in Diqdaqah, Ras Al Khaimah, United Arab Emirates.

to: Julphar is a public shareholding pharmaceutical company headquartered in Ras Al Khaimah, United Arab Emirates. Link for reference: http://www.julphar.net/en/about-us/what-we-do

CocaJola123 (talk) 04:47, 28 March 2019 (UTC) CocaJola123 (talk) 04:47, 28 March 2019 (UTC)

Not done: You should be able to edit the page now that you are autoconfirmed. --DannyS712 (talk) 03:02, 8 April 2019 (UTC)

Semi-protected edit request on 28 March 2019

Please change the second sentence

from: It was established in 1980 under Sheikh Saqr bin Mohammad al-Qassimi, the late ruler of Ras Al Khaimah and currently produces and distributes pharmaceutical products across five continents.

to: The company was established in 1980 under the guidance of His Highness Sheikh Saqr Bin Mohammed Al Qasimi, the late ruler of Ras Al Khaimah. It is one of the largest pharmaceutical manufacturers in the Middle East and Africa and one of the leading producers of insulin in the world. Link for reference: http://www.julphar.net/en/about-us/what-we-do

CocaJola123 (talk) 04:50, 28 March 2019 (UTC) CocaJola123 (talk) 04:50, 28 March 2019 (UTC)

Not done: You should be able to edit the page now that you are autoconfirmed. --DannyS712 (talk) 03:02, 8 April 2019 (UTC)

Semi-protected edit request on 28 March 2019

Please change the third sentence

from: Julphar produces therapeutic products which target a large range of pharmaceutical segments including consumer, endocrinology, antibiotics, cardiovascular, women's health, dermatology and gastroenterology.

to: Julphar's business is centered on three core business units – General Medicines, Julphar Diabetes Solutions and its consumer division, Julphar Life. The company's medicines target major therapeutic segments including Gastrointestinal Tract (GIT), Respiratory, Pain Management, Wounds and Scars, Anti-infectives, Anemia, Gynecology, Dermatology, Erectile Dysfunction and Cardiology.

CocaJola123 (talk) 04:52, 28 March 2019 (UTC) CocaJola123 (talk) 04:52, 28 March 2019 (UTC)

Not done: You should be able to edit the page now that you are autoconfirmed. --DannyS712 (talk) 03:02, 8 April 2019 (UTC)

Semi-protected edit request on 28 March 2019

Please change the third sentence

from: Julphar produces therapeutic products which target a large range of pharmaceutical segments including consumer, endocrinology, antibiotics, cardiovascular, women's health, dermatology and gastroenterology.

to: Julphar's business is centered on three core business units – General Medicines, Julphar Diabetes Solutions and its consumer division, Julphar Life. The company's medicines target major therapeutic segments including Gastrointestinal Tract (GIT), Respiratory, Pain Management, Wounds and Scars, Anti-infectives, Anemia, Gynecology, Dermatology, Erectile Dysfunction and Cardiology.

Link for reference: http://www.julphar.net/en/about-us/what-we-do

CocaJola123 (talk) 04:52, 28 March 2019 (UTC) CocaJola123 (talk) 04:52, 28 March 2019 (UTC)

Not done: You should be able to edit the page now that you are autoconfirmed. --DannyS712 (talk) 03:02, 8 April 2019 (UTC)

Semi-protected edit request on 28 March 2019

Please add a sentence to the end of the first para, which reads: The company employs 5,000 people and distributes products to more than 50 countries on five continents. Julphar's 16 internationally accredited facilities in Africa, the Middle East and Asia produce more than a million boxes of medicine a day.

Link for reference: http://www.julphar.net/en/about-us/what-we-do

CocaJola123 (talk) 04:55, 28 March 2019 (UTC) CocaJola123 (talk) 04:55, 28 March 2019 (UTC)

Not done: You should be able to edit the page now that you are autoconfirmed. --DannyS712 (talk) 03:02, 8 April 2019 (UTC)

Semi-protected edit request on 28 March 2019

In the right hand side box please change general manager to General Manager

CocaJola123 (talk) 04:57, 28 March 2019 (UTC) CocaJola123 (talk) 04:57, 28 March 2019 (UTC)

Not done: You should be able to edit the page now that you are autoconfirmed. --DannyS712 (talk) 03:02, 8 April 2019 (UTC)

Semi-protected edit request on 28 March 2019

Under Operations please update the following sentence

from: In 2012, Julphar will become the only company in the Middle East and North Africa Region to locally produce Recombinant DNA(r-DNA), the raw material used to make insulin.

to: In 2012, Julphar became the only company in the Middle East and North Africa Region to locally produce Recombinant DNA(r-DNA), the raw material used to make insulin.

Link for reference: http://www.julphar.net/en/about-us/what-we-do

CocaJola123 (talk) 04:59, 28 March 2019 (UTC) CocaJola123 (talk) 04:59, 28 March 2019 (UTC)

Not done: You should be able to edit the page now that you are autoconfirmed. --DannyS712 (talk) 03:02, 8 April 2019 (UTC)

Semi-protected edit request on 28 March 2019

Please add a section called History under Operations

CocaJola123 (talk) 05:03, 28 March 2019 (UTC) CocaJola123 (talk) 05:03, 28 March 2019 (UTC)

Not done: You should be able to edit the page now that you are autoconfirmed. --DannyS712 (talk) 03:02, 8 April 2019 (UTC)

Semi-protected edit request on 28 March 2019

Please update Julphar's logo from the one on the right hand side. Attached is the new logo. Link for reference: http://www.julphar.net/en

CocaJola123 (talk) 05:06, 28 March 2019 (UTC) CocaJola123 (talk) 05:06, 28 March 2019 (UTC)

Not done: You should be able to edit the page now that you are autoconfirmed. --DannyS712 (talk) 03:02, 8 April 2019 (UTC)